Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.57 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.56 |
| ▸ | MRGPRX4 | Q96LA9 | 8/20 | 0.55 |
| ▸ | TP53 | P04637 | 2/20 | 0.55 |
| ▸ | PKM | P14618 | 2/20 | 0.55 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.55 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.55 |
| ▸ | RELA | Q04206 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.55 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.50 |
| ▸ | MEP1B | Q16820 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30489978 | 1.00 | SLC7A5 (0.57) | SLC7A5FOLH1MRGPRX4TP53PKM | |
| SCHEMBL6115593 | 0.87 | SLC7A5 (0.55) | SLC7A5PKMNFKB1NFKB2RELA | |
| SCHEMBL8057216 | 0.86 | SLC7A5 (0.57) | SLC7A5RAB9ALOXL2 | |
| SCHEMBL2964543 | 0.86 | LOXL2 (0.68) | SLC7A5FOLH1MRGPRX4SMN1; SMN2RAB9A | |
| SCHEMBL12400239 | 0.85 | SLC7A5 (0.68) | SLC7A5PKMNFKB1NFKB2RELA | |
| SCHEMBL24031215 | 0.85 | SLC7A5 (0.56) | SLC7A5LOXL2MEP1B | |
| SCHEMBL968785 | 0.85 | SLC7A5 (0.52) | SLC7A5PKMNFKB1NFKB2RELA | |
| SCHEMBL3451761 | 0.85 | SLC7A5 (0.56) | SLC7A5LOXL2MEP1B | |
| SCHEMBL5271801 | 0.84 | MRGPRX4 (0.73) | MRGPRX4TP53PKMNFKB1NFKB2 | |
| SCHEMBL13185388 | 0.83 | SLC7A5 (0.51) | SLC7A5SMN1; SMN2RAB9ALOXL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025059562-A1 | SUBSTITUTED AMINOPYRIDINE COMPOUNDS AND METHODS OF TREATING DISEASE USING SAME | ATAVISTIK BIO, INC. (US) | 2025-03-20 | — | — | WO | disclosed |
| WO-2025054132-A1 | ANTIBACTERIAL COMPOUNDS | ARREPATH, INC. (US) | 2025-03-13 | — | — | WO | disclosed |
| WO-2023227666-A1 | PYRIMIDINONE COMPOUNDS FOR TREATING ACUTE INFLAMMATION | TES PHARMA S.R.L. (IT) | 2023-11-30 | — | — | WO | disclosed |
| US-20230219961-A1 | Pyridine acetamide derivative serving as CDK inhibitor, and preparation method therefor and use thereof | Suzhou Alphama Biotechnology Co., Ltd. (CN) | 2023-07-13 | — | — | US | disclosed |
| US-20230143425-A1 | IMPROVEMENTS RELATED TO SORBENT MEDIA | GENESIS SYSTEMS LLC | 2023-05-11 | — | — | US | disclosed |
| CN-115340555-A | Pyridine acetamide derivative as CDK inhibitor, and preparation method and application thereof | 苏州阿尔脉生物科技有限公司 | 2022-11-15 | — | — | CN | disclosed |
| CN-113173924-B | Pyridine acetamide derivative as CDK inhibitor, and preparation method and application thereof | 苏州阿尔脉生物科技有限公司 | 2022-07-19 | — | — | CN | disclosed |
| US-11254644-B2 | Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase | TES PHARMA S.R.L. (IT) | 2022-02-22 | — | — | US | disclosed |
| EP-3186242-B1 | INHIBITORS OF ALPHA-AMINO-BETA-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE | TES PHARMA S R L (IT) | 2021-10-06 | — | — | EP | disclosed |
| CN-113173924-A | Pyridine acetamide derivative as CDK inhibitor, and preparation method and application thereof | 苏州阿尔脉生物科技有限公司 | 2021-07-27 | — | — | CN | disclosed |
| EP-2411361-A1 | 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2012-02-01 | — | — | EP | disclosed |
| US-20100249139-A1 | 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS | HOFFMANN-LA ROCHE, INC. | 2010-09-30 | — | — | US | disclosed |
| WO-2010108902-A1 | 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-09-30 | — | — | WO | disclosed |
| US-7514468-B2 | Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-04-07 | — | — | US | disclosed |
| CN-1318403-C | Indoline derivatives substituted in the 6 position, their preparation and their use as medicaments | BOEHRINGER INGELHEIM PHARMA (DE) | 2007-05-30 | — | — | CN | disclosed |
| US-20060194813-A1 | Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2006-08-31 | — | — | US | disclosed |
| CN-1668589-A | Indoline derivatives substituted in the 6-position, their preparation and their use as medicaments | BOEHRINGER INGELHEIM PHARMA (DE) | 2005-09-14 | — | — | CN | disclosed |
| EP-1492537-A1 | MORPHOLINE DERIVATIVES WITH A SUBSTITUTED ACETAMIDE GROUP IN THE 2-POSITION FOR USE AS CCR-3 ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2005-01-05 | — | — | EP | disclosed |
| WO-2003097618-A1 | MORPHOLINYLMETHYLUREAS CCR-3 RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2003-11-27 | — | — | WO | disclosed |
| WO-2003082294-A1 | MORPHOLINE DERIVATIVES WITH A SUBSTITUTED ACETAMIDE GROUP IN THE 2-POSITION FOR USE AS CCR-3 ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249139-A1 | 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS | NR3C1, NR3C2, CRHR1 | SLC7A5 4174/4885FOLH1 3763/4885MRGPRX4 284/4885 |
| US-20060194813-A1 | Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions | KDR, FLT1, EGFR | SLC7A5 1259/4885FOLH1 3813/4885MRGPRX4 1582/4885 |
| US-20230219961-A1 | Pyridine acetamide derivative serving as CDK inhibitor, and preparation method therefor and use thereof | CDK9, CDK7, CDK8 | SLC7A5 4282/4885FOLH1 2791/4885MRGPRX4 2731/4885 |
| US-11254644-B2 | Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase | ACMSD, GLS, ALDH7A1 | SLC7A5 644/4885FOLH1 553/4885MRGPRX4 3607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.